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INTRODUCTION
and adolescents' quality of life, daily activities, and school absenteeism and can have long-term psychological implications. 3 Moreover, patients are at risk for continued symptoms in adulthood, and costs are substantial. [4] [5] [6] Standard medical care consists of reassurance, education and, dietary advice. 7 Despite ongoing efforts to identify causal and contributing factors in AP-FGIDs, successful management is complicated by an incomplete pathophysiological understanding. The biopsychosocial model, based on a complex interplay of genetic, physiological, and psychological factors, is conceptualizing the etiology of FGIDs. 7 It is hypothesized that pediatric AP-FGIDs are strongly associated with stress and psychological disorders such as anxiety and depression, 8 wherein the coping potentials of children with APFGIDs are low compared to those of healthy children. 9 Therefore, interventions such as cognitive behavioral therapy (CBT), hypnotherapy (HT), and yoga are aiming to teach alternative responses to stress. 10 Systematic reviews have concluded that CBT and HT offer beneficial effects for children with AP-FGIDs. 11, 12 The role of food in FGIDs has been revisited recently in the adult literature. 13, 14 Food may trigger symptoms in FGID patients who already have physiologic alterations, subsequently making them susceptive for hypersensitivity. 13 However, recognition which specific food components trigger symptoms is difficult and can lead to profusion of investigations and dietary therapies, largely based on expert opinion. 14 Two previous systematic reviews reported that fiber supplements are ineffective in treating AP-FGIDs, whereas conclusions were contradictory regarding probiotics. 15, 16 Treatment of children who have AP-FGIDs can be challenging, especially because high-quality evidence for pharmacologic interventions is lacking. 17 Although several systematic reviews summarizing different nonpharmacologic interventions exist, 11, 15 ,18 the present systematic review provides an up-to-date overview regarding the efficacy and safety of all nonpharmacologic treatments for pediatric AP-FGIDs. Such a comprehensive and recent overview is warranted.
METHODS

Literature search
The Cochrane Library and Medline databases were searched for systematic reviews and randomized controlled trials (RCTs) from inception to October 2013. Search terms used items related to pediatric AP-FGIDs and various nonpharmacologic treatments. To identify additional studies, reference lists of reviews and included studies were searched by hand. The full search strategy and keywords are available from the authors.
Study inclusion
Two authors (L.M.A.J.V. and M.M.T.) independently assessed eligibility of all abstracts. In case of disagreement, consensus was reached through discussion. Inclusion criteria were: (1) study was a systematic review or RCT; (2) study population comprised children aged 3 to 18 years; (3) diagnosis of recurrent abdominal pain (RAP), FAP, IBS, functional dyspepsia, abdominal migraine, or functional abdominal pain syndrome as defined by authors; (4) interventions were lifestyle advice such as physical exercise, dietary interventions (fiber supplements; lactose-, gluten-, histamine-, and carbonic acid-free diets; and fluid intake), behavioral interventions such as HT,
CBT, prebiotics and probiotics and alternative medicine (acupuncture, homeopathy, mind-body therapy, musculoskeletal manipulations such as osteopathic and chiropractic manipulations and spiritual therapies such as yoga); (5) the intervention was compared with placebo, no treatment, any other nonpharmacologic treatment or pharmacologic agent; and (6) outcomes were abdominal pain intensity and/or frequency, quality of life, functional disability (e.g. school absence), and adverse effects. Exclusion criteria were: (1) treatment arm with <10 patients;
and (2) language other than English. Potentially relevant studies and studies in which title and abstract provided insufficient information were retrieved as full-text articles.
Quality assessment and data extraction
Two authors (L.M.A.J.V. and M.M.T.) independently rated the methodologic quality of the included studies using the Cochrane risk of bias tool. For each outcome, quality of evidence was assessed using the GRADE approach and was categorized as very low, low, moderate, or high.
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The same authors extracted data from included studies using structured data extraction forms containing items on participants, study setting, interventions, and outcomes. Disagreements were resolved through consensus or by a third reviewer (M.A.B.).
Data analysis
Dichotomous outcomes were analyzed as odds ratios (ORs) or relative risks (RRs) along with 95% confidence intervals (CIs). For continuous outcomes, mean differences (MDs) with 95%
CIs were reported. Heterogeneity was quantified by using χ2 tests and the I 2 statistic, which can be interpreted as the percentage of the total variation between studies that is attributable to heterogeneity rather than chance. A value of 0% indicates no observed heterogeneity, whereas larger values show increasing heterogeneity. If heterogeneity was not revealed, results of the fixed effect model are presented. If there was substantial heterogeneity (>50%), the random effect model was used.
RESULTS
A total of 568 potentially relevant articles and abstracts were identified ( Figure 1 ). After removal of duplicates (n=316) and abstracts screening (n=210), 42 full-text articles were assessed for eligibility. Twenty-nine articles were excluded because of the following: adult study population (n=6), irrelevant outcome measures, such as improvement in rectal sensitivity or gastrointestinal symptoms without abdominal pain (n=2), no systematic review or RCT (n=15), or inclusion of only trials which were already included by another systematic review (n=6). Thirteen articles remained for analysis: 7 systematic reviews 11, 12, 15, 16, 18, 22, 23 (including 18 RCTs) and 6 RCTs. [24] [25] [26] [27] [28] [29] Two included trials concerned follow-up studies, 26,30 which will be discussed by their original studies.
31,32
Two systematic reviews 11, 12 included studies with <10 patients per treatment arm and these studies were therefore excluded [33] [34] [35] Articles identified by database searching n=567
Result of hand search: n=1
Removal of duplicates n=316
Total number of articles identified n=568
Number of articles screened n=252
Full text articles assessed for eligibility n=42
Exclusion based on abstract n=210
Not meeting inclusion criteria n=29
Included articles n=13 (including 24 studies) Figure 1 . 
Methodological quality
The overall quality of evidence was very low to moderate. Appendix I shows the GRADE evidence profiles. Concealment of allocation was unclear in 6 studies. 36, [44] [45] [46] 48, 49 Due to the nature of HT, CBT, WSD, and yoga, blinding was not possible for the caregiver or patient. 31 Because participants were recruited through physician referral and flyers, these patients were therefore seriously motivated, which can cause bias.
Dietary interventions
No studies were included evaluating gluten-, histamine-and carbonic acid-free diets or fluid intake.
Fiber supplements
Two systematic reviews 15 16 included a third trial with 90 children (aged 7 to 17 years) receiving 4 weeks of glucomannan or identical placebo. 38 Pain severity was assessed by using the Faces Pain Scale Revised(6 faces ranging from relaxed to intense pain). 51 School absenteeism and changes in daily activities were self-reported. The primary outcome in all studies was degree of improvement based on abdominal pain frequency or intensity. with abnormal lactase activity (12-20 U) were excluded: 69 children received 6 weeks of a lactose-containing or lactose-free infant formula. Abdominal pain was documented in diaries by parents. Remarkably, 31 children were excluded due to a lack of compliance; 38 children remained. A lactose tolerance test was performed, the results of which were used to divide children into 2 groups: lactose malabsorbers (N=21) and lactose absorbers (N=17). Increased symptoms were described in 48% of the lactose malabsorbers and 24% of lactose absorbers after lactose intake; however, P values were not reported. Forty of the 69 children continued with a 12-month lactose-free diet. Improvement of abdominal pain after 12 months was similar in both groups (40% vs 38%). Detailed data were not reported, however, and meta-analysis and GRADE evidence profiling were therefore not possible.
Dearlove et al 39 included 21 children with RAP in a double-blind, single cross-over study. After 2 weeks of collecting baseline data, all children underwent a 2-week lactose-free diet, followed by another 2 weeks of lactose tonic (2 g/kg) or similarly flavored placebo. Primary and secondary outcomes were not specified. After 3 months, parents were asked whether their child's symptoms (including abdominal pain) were better, worse, or the same. There was no difference in the number of children claiming relief from lactose-free or lactose-containing formula. LGG vs placebo Dosage: 3x10 9 CFU, twice daily Pain Disability Index to assess impairment in 12 daily activities. HT had a significant beneficial effect on the self-reported disability compared to control subjects (MD -9.14 [95% CI -14.41
to -3.87]). 25 Van Tilburg et al used the Functional Disability Inventory. 44 Children receiving HT exhibited a significant reduction of disability compared to control subjects (P=0.01).
Two studies did not describe differences in school absenteeism between either treatment group. 32,44 In 1 trial, school absenteeism was seldom reported, and therefore no calculation was performed. 25 One child dropped out because of transient headaches after listening to the CD. 44 Gulewitsch et al 25 reported no side effects.
Cognitive Behavioral Therapy
Two systematic reviews 12, 22 
Written self-disclosure (WSD)
Wallander et al 29 evaluated WSD in addition to standard care in 63 children (aged 11-18 years) with RAP. In three 20-minute sessions, patients were asked to write about their "deepest thoughts and feelings about the most distressing experience in their life". Primary and secondary outcomes were not specified. Seven patients were lost to follow-up and excluded from analyses.
Abdominal pain frequency was rated using a 6-point scale. Although there were no differences at 3 months, pain frequency was significantly less after WSD and standard care at 6-month follow-up compared with standard care alone (F [1,51] = 6.50, P=0.014, Cohen's d = 0.61).
Physical and psychosocial quality of life was measured by using the Pediatric Quality of Life Inventory, and no significant differences were reported. Likert scale. After treatment, a significant reduction in the abdominal pain score of 1.0±0.2 was reported in the VSL#3 group versus 0.5±0.2 in control subjects (P<0.05). One study evaluated school absenteeism, but no significant difference was found. 42 No adverse effects of LGG were reported, although it was unclear in 2 studies how adverse effects were assessed. 41, 42 No studies were included on prebiotics.
Pre-or probiotics
Alternative medicine
One study of the systematic review by Birdee et al 23 was included regarding alternative therapy.
Kuttner et al 50 compared 14 children receiving yoga to 11 wait-list control subjects. After 4 weeks, questionnaires were completed, and control subjects received 4 weeks of yoga and completed additional questionnaires. Pain intensity was measured on a numeric scale of 1 to 10. Results before the crossover phase were not reported because of baseline differences.
Functional disability decreased after yoga, but increased in control subjects (MD -9.60 [ 95% CI -19.66 to 0.46]). Primary or secondary outcomes were not specified.
No studies were included evaluating acupuncture, homeopathy, mind-body therapy, musculoskeletal manipulations such as osteopathic and chiropractic manipulations. Dietary interventions are frequently used in AP-FGIDs, because many patients and some physicians consider symptoms to be meal related. 55 Fiber supplementation is believed to be helpful because it softens stools and enhances colonic transit. 56 However, studies in children and adolescents evaluating ispaghula husk and glucomannan found no favorable effects. 36, 38 Improvement in abdominal pain frequency was reported after administration of corn fiber, 37 but questions were raised whether statistical analyses were adequate. Re-analyses by Huertas-Ceballos et al 15 failed
to replicate the findings. Adult studies produced conflicting results and a meta-analysis reported only beneficial effects for ispaghula husk. 56 The main component of PHGG is galactomannan, which softens stool, improves fecal output and increases bulk capacities. 57 PHGG treatment in IBS children found a reduced frequency in IBS symptoms, but pain intensity was not decreased.
24
Results of an open PHGG trial in adult patients with IBS produced significant improvements in gastrointestinal symptoms, quality of life, and psychological distress, but the effects tended to fade out after the 12-week treatment period. 57 Malabsorption and intolerance to carbohydrates such as fructose and lactose are believed to cause symptoms such as bloating, diarrhea and abdominal pain. 55 However, neither lactose nor fructose intolerance was established as a cause of pain in 220 children with RAP in a recent study, 58 and lactose restriction did not improve symptoms in pediatric trials. 39, 40 Recently, diets of low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) have been extensively studied in adults. FODMAPs are poorly absorbed short-chain carbohydrates, which may cause gas production, bloating, and abdominal pain. 59 A low FODMAP diet seems beneficial in adult IBS trials, but due to heterogeneity in study design and outcomes and because of unknown long-term safety and efficacy, definitive conclusions cannot be drawn. 60 Recently, a randomized, double blind, crossover trial in 33 IBS children reported improvement in abdominal pain after receiving a 48-hour low FODMAP diet. 61 Although these results seem promising, more long-term studies are needed to further assess the efficacy and safety of a low FODMAP diet in children and adolescents.
In HT, suggestions toward control and normalization of gut functioning, ego-strengthening, and stress reduction are conveyed to patients after inducing a hypnotic state. 62 Results of studies in children and adolescents found significantly lower abdominal pain levels and symptom scores after HT, either through individual or group sessions with therapists or with self-exercises on a CD. 25, 32, 44 Effects persist up to 5 years after treatment. 30 Results are in accordance with adult IBS trials showing that HT is superior to a variety of control treatments, with long-lasting effects. [63] [64] [65] [66] Working mechanisms of HT are still poorly understood, but outcomes of adult studies hypothesize that HT affects both physiological processes, such as colonic motility and pain processing brain regions, and psychological factors such as stress and dysfunctional cognitions. [67] [68] [69] CBT aims to change attitudes, cognitions and behavior that may play a role in generating or maintaining symptoms and is effective in improving pain and other IBS symptoms in adults. 70 Trials in children and adolescents also indicate beneficial effects of CBT, especially CBT-family, in improving pain and disability and effects appear to be long-lasting. data are lacking on the efficacy and safety of almost all forms of this treatment in these children and adolescents. Yoga may address psychosocial factors and decrease stress. 76 Kuttner et al 50 reported significantly lower levels of functional disability and gastrointestinal symptoms after yoga, but it is noteworthy that P values <0.1 were considered reflective of statistical trends worthy of interpretation. However, a pilot study in children and adolescents aged 8 to 18 years with IBS and FAP also showed significant short-term improvement in abdominal pain frequency and intensity. 76 It thus seems worthwhile to further explore efficacy of yoga. Because treatment protocols in CBT, HT, and yoga all incorporate relaxation exercises, one might hypothesize that relaxation training alone can also be beneficial in AP-FGIDs. This therapeutic approach may be interesting to address in future research because it has been shown to be effective in children and adolescents with recurrent headaches as well. 77 The methodologic quality of the included studies varied from very low to moderate, and the results should therefore be interpreted cautiously. The low quality was mainly due to small sample sizes, lack of adequate follow-up, substantial dropout rates, or considerable risk of bias. However, it should be taken into account that blinding of patients and caregivers A limited number of RCTs (n=8) reported on adverse effects, thereby hindering interpretation of results on safety. However, in those studies, no serious adverse effects were shown, apart from a small number of children reporting gas or diarrhea. 37 In interpreting FGID trials, the placebo effect may play an important role. Placebo responses in trials of adults with IBS vary from 16.0% to 71.4%, 78 and high placebo rates up to 53% were reported in RCTs on children and adolescents. 41, 43, 79 High placebo responses may also display natural course of FGIDs with fluctuating symptoms. 80 Improving the patient-practitioner relationship and active listening approaches are essential in mediating placebo responses, which may be especially important in nonpharmacologic therapies in which contact with therapists is mostly frequent.
81,82
CONCLUSIONS
To date, high-quality studies on nonpharmacologic treatments in pediatric AP-FGIDs are lacking, and the need for these studies is evident. However, available evidence indicates beneficial effects of HT, CBT and probiotics (LGG and VSL#3) in some children. Data on fiber supplementation for children and adolescents with AP-FGIDs is inconclusive, but PHGG may be an option. No serious adverse effects were reported.
Since symptoms may resolve without active treatment in a significant proportion of children, the first step in management may consist of physician reassurance and education. However, approximately one-third of children continue to experience symptoms. 83 Clinicians may consider HT, CBT or probiotics (LGG and VSL#3), especially in children with persisting symptoms.
Additional high-quality studies are required in children with mild symptoms as well as severe symptoms to further assess the effectiveness of nonpharmacologic therapies and to identify factors predicting response, with the goal of optimizing and tailoring individual treatment.
Because abdominal pain is the key symptom in AP-FGIDs and to decrease heterogeneity, we emphasized the importance of including abdominal pain severity, frequency, and/or intensity as a primary outcome measure in trials evaluating (non)pharmacologic treatments for AP-FGIDs.
In addition, adverse effects need to be reported systematically to better assess safety. Total number of events is less than 300 and 95% CI around the pooled estimate of effect includes both 1) no effect and 2) appreciable benefit or appreciable harm. One study only. 4 Low sample size. 5 Van Tilburg (2009) 6 Concealment of allocation unclear. Intervention unblinded. 7 In the article not sufficient data are given to present (complete) results. could not be blinded. In total 38/44 participants completed the study but we were unable to ascertain the numbers by group to which they were allocated. 2 One study only. 3 Low sample size. 4 Concealment of allocation was unclear. 5 In the article not sufficient data are given to present (complete) results. 6 There is significant differential loss to follow-up in this study with outcome data are available for 40/46 patients in the intervention group and 29/40 in the control group. Concealment of allocation and blinding of outcomes was unclear. Duration of treatment has not been described. 2 One study only. 3 Low sample size (N=48). 4 In the article not sufficient data are given to present (complete) results. Attrition is described, significant differences between completers and non-completers are not reported. Randomization unclear. Baseline differences.
2 One study only. 3 Participants were a volunteer group who had been referred by providers or responded to notices regarding the study. Consequently, they may not be representative of the larger population of families and children with FAP.
Question: Should cognitive behavioral group therapy vs wait-list be used for functional abdominal pain? Settings: not reported In Bausserman the lost-to-follow up was >20%.
Question: Should VSL#3 vs placebo be used for IBS (ROME II)? Settings: 5 pediatric tertiary care centers No details about randomization mentioned. 2 One study only. 3 Only children with IBS have been included. 4 Low sample size. 5 In the article not sufficient data are given to present (complete) results.
GRADE evidence profile Alternative medicine One study only. 3 Children aged 11-18 years with IBS.
